Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Slim Fast, other supplements recalled

This article was originally published in The Tan Sheet

Executive Summary

Supplement firm Universal ABC Beauty Supply International voluntarily recalls 34 products found by FDA to contain an undeclared substance, sibutramine, a prescription weight-loss drug, the Brooklyn, N.Y.-based company says in an April 20 release. The products, including Slim Fast, ProSlim, and Slim 3in1 formulas, have not been approved by the agency and the ingredient is known to potentially cause cardiovascular issues in some users, the firm notes. When FDA announed a crackdown on adulterated weight-loss products in January, the agency warned that selling unapproved drugs may lead to criminal action, though it did not identify the firms suspected of marketing the products (1"The Tan Sheet" Jan. 5, 2009, p. 8). Universal's recalled products were on FDA's list of more than 70 products identified as tainted with undeclared drugs. Only three products had been recalled through April 8, FDA said

You may also be interested in...



FDA Warns Of Possible Criminal Charges Against Weight-Loss Product Firms

FDA's enforcement action against 28 weight-loss products found to contain undeclared pharmaceutical ingredients drew applause from GlaxoSmithKline, marketer of alli, the only OTC drug approved for weight loss in the U.S

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS102857

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel